用非特异性免疫促进剂开启抗病毒抗肿瘤治疗革命大门

Open the Therapeutic Revolution Door of Antiviral Antitumor with Improving Body Systemic Nonspecific Immunity

摘要: 目的：本文通过帕米卡®在治疗荷瘤小白鼠上的安全性和显著效果，阐明了使用非特异性免疫促进剂作为广谱抗肿瘤抗病毒治疗的可行性。方法：用肺癌、乳腺癌、黑色素瘤细胞造成荷瘤小白鼠模型，再用帕米卡制剂隔天注射或喷鼻0.1~0.2 ml/次(3 mg/ml)治疗并设阳性对照药及溶媒阴性对照，观察对小白鼠肿瘤抑制率及其瘤体重量、肿瘤转移、荷瘤小白鼠脾重，体重、存活数等。结果：帕米卡对几种荷瘤小白鼠有效性统计学测定效果与阴性对照比较p < 0.05~0.0001，甚至优于阳性对照PD1、紫杉醇(PTX)法定抗癌药。结论：帕米卡非特异性免疫制剂对几种荷瘤小白鼠具有安全性良好和极其显著的治疗效果，表明了这种新思路和新方法抗肿瘤抗病毒是可行的，具有重大现实意义。

Abstract: Purpose: This paper showed feasibility which has good safety and significant effectiveness of Pamica® with improving the body systemic nonspecific immunity to mice bearing several tumors to be antivirus antitumor. Methods: To set up the models of mice bearing non-small cell lung cancer, breast cancer, melanoma and then to inject or spray the Pamica 0.1 - 0.2 ml/mouse (3 mg/ml) one day apart and to test the tumors inhibition rate and its weight, metastasis, spleen weight, body weight, survival number compared with the positive and negative control groups. Results: In the mice bearing non-small cell lung cancer, breast cancer, and melanoma, the efficacy of Pamica showed significant difference (p < 0.05 - 0.0001) which even overmatched official anticancer drugs PD1 and PTX. Conclusion: Pamica, the non-specific immunity preparation, has good safety and very significant effectiveness to mice bearing several tumors and it points out its feasibility as broad-spectrum antivirus antitumor by this new idea and methods and it has great practical significance.